Delving into the Latest Updates on Grass pollen allergoids(Allergopharma GmbH & Co. KG) with Synapse

Overview

Basic Info

Drug Type

Allergen extract

Synonyms

Allergovit 6 Grasses, Grass pollen allergoids

Target-

Mechanism

Immunomodulators

Therapeutic Areas

Immune System Diseases

Active Indication

AnaphylaxisHypersensitivity

Inactive Indication

Allergic rhinoconjunctivitisRhinitis, Allergic, Seasonal

Originator Organization

Allergopharma GmbH & Co. KG

Active Organization

Allergopharma GmbH & Co. KG

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

NL (11 Jun 2013),

Anaphylaxis

Regulation-

Login to view timeline

The primary objective of the pilot study is to compare inflammatory responses in blood sera from patients receiving first allergen immunotherapy (AIT) with aluminium (Alum), microcrystalline tyrosine (MCT), or a combination of MCT and monophosphoryl lipid A (MPLA) as adjuvants. The AIT products are containing allergen extracts of grass and tree pollen). Blood is collected before as wells as one day, seven days, and 6-7 weeks after first AIT, and the blood is analysed for content of inflammatory proteins and antibodies.

Start Date05 Nov 2019

Sponsor / Collaborator

University of Zurich

NCT02297490 / TerminatedPhase 2

Evaluation of the Utility of an Environmental Exposure Chamber (EEC) for Assessing Efficacy of Specific Immunotherapy (SIT) in Pivotal Clinical Trials

The study will explore how allergy symptoms experienced during the grass pollen season compare to symptoms experienced in the Environmental Exposure Chamber (EEC).
There are 2 treatments in this study. Both treatments are injected under the skin. Allergovit® Grasses works by helping the body's immune system get used to grass-pollen before the grass pollen season begins which may lead to decreased sensitivity and reduced allergy symptoms during the grass season. Placebo treatment does not contain grass pollen mixture, and is not expected to reduce allergic symptoms overtime.

Start Date01 Jan 2014

Sponsor / Collaborator

Allergopharma GmbH & Co. KG

[+1]

NCT00841256 / CompletedPhase 3

... Study to Evaluate Efficacy and Safety of Perennial Sublingual SIT With a Solution of Grass Pollen Allergen ... in Children With Clinically Relevant Grass Pollen Sensitivity in Comparison to a ... Standard Treatment With Add on Placebo

Evaluation of safety and efficacy of sublingual immunotherapy with grass pollen allergens formulated as solution in comparison to a symptomatic standard treatment with add on placebo in grass pollen allergic children suffering from allergic rhinitis/rhinoconjunctivitis with or without bronchial asthma.

Start Date01 Feb 2008

Sponsor / Collaborator

Allergopharma GmbH & Co. KG

100 Clinical Results associated with Grass pollen allergoids(Allergopharma GmbH & Co. KG)

Login to view more data

100 Translational Medicine associated with Grass pollen allergoids(Allergopharma GmbH & Co. KG)

Login to view more data

100 Patents (Medical) associated with Grass pollen allergoids(Allergopharma GmbH & Co. KG)

Login to view more data

2

Literatures (Medical) associated with Grass pollen allergoids(Allergopharma GmbH & Co. KG)

01 Jan 1990·Journal of Allergy and Clinical ImmunologyQ1 · MEDICINE

Frequency of booster injections of allergoids

Q1 · MEDICINE

Article

Author: Peter S. Creticos ; David G. Marsh ; Philip S. Norman

In 1982, 43 ragweed-sensitive patients receiving maintenance injections of full doses of ragweed allergoid were selected for a study of the immunologic and clinical efficacy of booster injections only four times a year. These patients had participated for 2 to 7 years as part of a trial of mixes of up to four allergoids to common pollens in the mid-Atlantic area tailored to each patient's skin test sensitivity. They were divided into a group (21 patients) to receive injections every 3 months and a group (22 patients) to receive injections about every 6 weeks (eight injections per year). Patients were rerandomized after 1 year so that half of each original group switched to the alternate treatment, and this program was continued until after the ragweed season of 1985. Thirty-four patients were still under study the last year. Doses, per injection, were 100 allergoid units (1 allergoid unit equals 100 PNU) of each allergen in the mixture. Symptom scores during the 8 weeks of each of the four ragweed seasons were not significantly higher in the 3-month treated group. IgG antibody levels to Amb a I (antigen E) were followed until early 1984 and were not significantly different in the two groups, even though the 6-week treated patients received a two times higher cumulative dose per year. Rates of local and systemic reactions (percent of injections eliciting reactions) were not different in the groups, which means that the 3-month treated group had about half as many reactions by virtue of taking half as many injections.(ABSTRACT TRUNCATED AT 250 WORDS)

01 May 1970·Immunology

Studies on "allergoids" prepared from naturally occurring allergens. I. Assay of allergenicity and antigenicity of formalinized rye group I component.

Article

Author: Lichtenstein, L M ; Campbell, D H ; Marsh, D G

100 Deals associated with Grass pollen allergoids(Allergopharma GmbH & Co. KG)

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	V01AA02	-

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Anaphylaxis	NL	Allergopharma GmbH & Co. KG	11 Jun 2013
Hypersensitivity	-	Allergopharma GmbH & Co. KG	-

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Rhinitis, Allergic, Seasonal	Phase 1	DE	Allergopharma GmbH & Co. KG	29 Oct 2015
Allergic rhinoconjunctivitis	Phase 1	DE	Allergopharma GmbH & Co. KG	01 Jan 2004
Anaphylaxis	Phase 1	DE	Allergopharma GmbH & Co. KG	01 Jan 2004